WO2009060473A3 - Injectable compositions, processes and uses thereof - Google Patents

Injectable compositions, processes and uses thereof Download PDF

Info

Publication number
WO2009060473A3
WO2009060473A3 PCT/IN2008/000757 IN2008000757W WO2009060473A3 WO 2009060473 A3 WO2009060473 A3 WO 2009060473A3 IN 2008000757 W IN2008000757 W IN 2008000757W WO 2009060473 A3 WO2009060473 A3 WO 2009060473A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
pharmaceutically acceptable
processes
injectable compositions
biocompatible
Prior art date
Application number
PCT/IN2008/000757
Other languages
French (fr)
Other versions
WO2009060473A2 (en
Inventor
Rajesh Jain
Sukhjeet Singh
Sampath Kumar Devarajan
Original Assignee
Panacea Biotec Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Limited filed Critical Panacea Biotec Limited
Publication of WO2009060473A2 publication Critical patent/WO2009060473A2/en
Publication of WO2009060473A3 publication Critical patent/WO2009060473A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Injectable depot gel or implant compositions comprising at least one active agent(s) selected from a group comprising antipsychotics, aromatase inhibitors, alpha-1 adrenergic blocking agents, acetylcholinesterase inhibitors, and pharmaceutically acceptable salts, derivatives, isomers, polymorphs, solvates, hydrates, analogues, enantiomers, tautomeric forms or mixtures thereof; at least one biocompatible bioerodible polymer(s); at least one biocompatible non-toxic solvent(s) and optionally one or more pharmaceutically acceptable excipient(s) are provided. The present invention also describes process for preparation of such compositions and method of using such compositions.
PCT/IN2008/000757 2007-11-06 2008-11-06 Injectable compositions, processes and uses thereof WO2009060473A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2321DE2007 2007-11-06
IN2321/DEL/2007 2007-11-06

Publications (2)

Publication Number Publication Date
WO2009060473A2 WO2009060473A2 (en) 2009-05-14
WO2009060473A3 true WO2009060473A3 (en) 2009-10-15

Family

ID=40626309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000757 WO2009060473A2 (en) 2007-11-06 2008-11-06 Injectable compositions, processes and uses thereof

Country Status (3)

Country Link
AR (1) AR070033A1 (en)
CL (1) CL2008003305A1 (en)
WO (1) WO2009060473A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
ES2390439B1 (en) * 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. INJECTABLE COMPOSITION
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
ES2589106T3 (en) * 2010-05-31 2016-11-10 Laboratorios Farmaceuticos Rovi, S.A. Injection controlled antipsychotic composition
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
HUE057236T2 (en) * 2010-05-31 2022-04-28 Farm Rovi Lab Sa Compositions for injectable in-situ biodegradable implants
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
MX339196B (en) * 2010-10-28 2016-05-16 Aequus Pharmaceuticals Inc Aripiprazole compositions and methods for its transdermal delivery.
MA34832B1 (en) 2010-12-29 2014-01-02 Medincell BIODEGRADABLE DRUG DELIVERY COMPOSITIONS
MX342675B (en) 2011-03-10 2016-10-07 Xeris Pharmaceuticals Inc Stable formulations for parenteral injection of peptide drugs.
HUE032109T2 (en) 2011-03-18 2017-08-28 Alkermes Pharma Ireland Ltd Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
US8980298B2 (en) 2011-10-24 2015-03-17 Braeburn Pharmaceuticals Bvba Sprl Implantable tizanidine compositions and methods of treatment thereof
KR20140103927A (en) * 2011-10-24 2014-08-27 엔도 파마슈티컬즈, 솔루션스 아이엔씨. Implantable drug delivery compositions and methods of treatment thereof
EA027744B1 (en) 2011-10-31 2017-08-31 Ксерис Фармасьютикалс, Инк. Formulations for the treatment of diabetes mellitus
EP2827868B8 (en) 2012-03-19 2019-12-18 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
NZ630428A (en) * 2012-03-19 2017-02-24 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising benzyl alcohol
JP6219918B2 (en) * 2012-03-19 2017-10-25 アルカームス ファーマ アイルランド リミテッド Pharmaceutical composition comprising glycerol ester
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
EP3718536A1 (en) 2012-09-19 2020-10-07 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20160022571A1 (en) * 2013-03-14 2016-01-28 Braeburn Pharmaceuticals Bvba Sprl Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
MA39495A (en) 2014-03-20 2015-09-24 Alkermes Pharma Ireland Ltd ARIIPIPRAZOLE FORMULATIONS WITH HIGHER INJECTION RATES
CN106573106B (en) 2014-08-06 2021-06-22 Xeris药物公司 Syringe, kit and method for intradermal and/or subcutaneous injection of a paste
CN104189954B (en) * 2014-09-19 2017-03-29 中国科学院长春应用化学研究所 A kind of in-situ solidifying tissue engineering bracket and preparation method thereof
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
CA2994704A1 (en) * 2015-08-03 2017-02-09 Tolmar International Limited Liquid polymer delivery system for extended administration of drugs
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
KR102033686B1 (en) * 2017-05-19 2019-10-18 보령제약 주식회사 Microneedle transdermal patch comprising donepezil
AU2018275686B2 (en) 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
GB2568526A (en) * 2017-11-20 2019-05-22 Rebio Tech Oy Composition
CN112423754A (en) 2018-03-05 2021-02-26 奥克梅斯制药爱尔兰有限公司 Aripiprazole administration strategy
PE20210047A1 (en) * 2018-06-12 2021-01-08 Farm Rovi Lab Sa INJECTABLE COMPOSITION
AR116501A1 (en) * 2018-09-25 2021-05-12 Tolmar Int Ltd LIQUID POLYMER DELIVERY SYSTEM FOR EXTENDED DRUG ADMINISTRATION
US11911499B2 (en) * 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
CN113209370B (en) * 2020-01-21 2023-11-28 渼颜空间(河北)生物科技有限公司 Biodegradable injection filler, preparation method and application thereof
EP4362932A1 (en) * 2021-06-30 2024-05-08 The University of North Carolina at Chapel Hill Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery
WO2023116517A1 (en) * 2021-12-24 2023-06-29 四川科伦药物研究院有限公司 Continuous delivery preparation capable of being stably released and preparation method therefor
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0950403A2 (en) * 1998-04-14 1999-10-20 Atrix Laboratories, Inc. Emulsions for in-situ delivery systems
WO2000024374A1 (en) * 1998-10-28 2000-05-04 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2006053175A2 (en) * 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
WO2007026145A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Prolonged release formulations comprising anastrozole
WO2008041245A2 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331311B1 (en) * 1996-12-20 2001-12-18 Alza Corporation Injectable depot gel composition and method of preparing the composition
EP0950403A2 (en) * 1998-04-14 1999-10-20 Atrix Laboratories, Inc. Emulsions for in-situ delivery systems
WO2000024374A1 (en) * 1998-10-28 2000-05-04 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
WO2002049573A2 (en) * 2000-12-18 2002-06-27 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
WO2006053175A2 (en) * 2004-11-10 2006-05-18 Qlt Usa Inc. A stabilized polymeric delivery system
WO2007026145A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Prolonged release formulations comprising anastrozole
WO2008041245A2 (en) * 2006-10-05 2008-04-10 Panacea Biotec Ltd. Injectable depot composition and it's process of preparation

Also Published As

Publication number Publication date
AR070033A1 (en) 2010-03-10
WO2009060473A2 (en) 2009-05-14
CL2008003305A1 (en) 2009-06-05

Similar Documents

Publication Publication Date Title
WO2009060473A3 (en) Injectable compositions, processes and uses thereof
WO2003062248A3 (en) N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2010026436A3 (en) 1,3, 4, 6, 7, 11b-hexahydro-benzo[alpha]quinolizines for the treatment of hyperkinetic movement and related disorders
WO2003073986A3 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists
WO2007027527A3 (en) Isoindole-imide compounds and compositions comprising and methods of using the same
WO2007002313A3 (en) Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants
UA94964C2 (en) 5-substituted quinazolinone derivatives, composition containing thereof and use thereof
NO20076288L (en) Pharmaceutical compositions including imatinib and a release-lowering agent
WO2007002635A3 (en) C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
MX2009012847A (en) Dipeptide analogs as coagulation factor inhibitors.
WO2004112710A3 (en) COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß
WO2004058149A3 (en) 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles
TNSN07490A1 (en) Pharmaceutical sustained release compositions and processes thereof
WO2008048981A3 (en) Indole antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
WO2020257549A3 (en) Compounds for treatment of pd-l1 diseases
HK1120506A1 (en) Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4)
WO2011003018A3 (en) Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof
WO2003074008A3 (en) Aminoalkylphosphonates and related compounds as edg receptor agonists
WO2005032465A3 (en) 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
WO2005105088A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
WO2005094810A3 (en) Novel pharmaceutical compositions
WO2008157751A3 (en) Substituted imidazoheterocycles
IN2014KN02886A (en)
WO2004066965A3 (en) Method of preventing surgical adhesions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08846791

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08846791

Country of ref document: EP

Kind code of ref document: A2